Publications by authors named "Andrew Clamp"

52Publications

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial.

Trials 2020 Sep 17;21(1):802. Epub 2020 Sep 17.

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13063-020-04718-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495966PMC
September 2020

Progression-free survival in the ICON8 trial - Authors' reply.

Lancet 2020 09;396(10253):757

Department of Medical Oncology, The Christie National Health Service Foundation Trust and University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(20)31177-6DOI Listing
September 2020

First-Line Management of Advanced High-Grade Serous Ovarian Cancer.

Curr Oncol Rep 2020 Jun 4;22(6):64. Epub 2020 Jun 4.

Department of Medical Oncology, Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-020-00933-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270049PMC
June 2020

Discharging Women with Advanced Ovarian Cancer on Home Parenteral Nutrition: Making and Implementing the Decision.

Nutrients 2020 Jan 7;12(1). Epub 2020 Jan 7.

Faculty of Medicine, Biology and Health, and Manchester Academic Health Science Centre, University of Manchester, Oxford Road, Manchester M13 9PL, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nu12010166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019843PMC
January 2020

Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.

Gynecol Oncol 2020 03 10;156(3):545-551. Epub 2020 Jan 10.

Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.01.005DOI Listing
March 2020

Prevalence of germline pathogenic variants in sequential epithelial ovarian cancer cases.

J Med Genet 2019 05 25;56(5):301-307. Epub 2019 Jan 25.

Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jmedgenet-2018-105792DOI Listing
May 2019

The Human In Vivo Biomolecule Corona onto PEGylated Liposomes: A Proof-of-Concept Clinical Study.

Adv Mater 2019 Jan 28;31(4):e1803335. Epub 2018 Nov 28.

Nanomedicine Lab, Faculty of Biology, Medicine and Health, The University of Manchester, AV Hill Building, Manchester, M13 9PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/adma.201803335DOI Listing
January 2019

Home parenteral nutrition for people with inoperable malignant bowel obstruction.

Cochrane Database Syst Rev 2018 08 10;8:CD012812. Epub 2018 Aug 10.

School of Health Sciences, The University of Manchester, and Manchester Academic Health Science Centre, Oxford Road, Manchester, UK, M13 9PL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD012812.pub2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513201PMC
August 2018

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

Cancer Chemother Pharmacol 2018 04 20;81(4):647-658. Epub 2018 Feb 20.

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3532-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854713PMC
April 2018

Malignant bowel obstruction in advanced ovarian cancer.

Future Oncol 2017 Mar 18;13(6):513-521. Epub 2017 Jan 18.

The Christie NHS Foundation Trust & Institute of Cancer Sciences, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0431DOI Listing
March 2017

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.

J Clin Oncol 2015 Nov 15;33(31):3576-82. Epub 2015 Jun 15.

Amit M. Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada; Sandro Pignata, Istituto Nazionale Tumori "Fondazione G Pascale"-Istituto Di Ricovero e Cura a Carattere Scientifico, Naples, Italy; Andres Poveda, Instituto Valenciano de Oncologia, Valencia, Spain; Mary McCormack, University College Hospital, London; Andrew Clamp, Institute of Cancer Sciences-University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom; Benjamin Schwartz, Island Gynecologic Oncology, Brightwaters, NY; Jonathan Cheng, Xiaoyun Li, and Kristy Campbell, Merck, Kenilworth, NJ; and Pierre Dodion and Frank G. Haluska, ARIAD Pharmaceuticals, Cambridge, MA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/31/3576.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.8871
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.8871DOI Listing
November 2015

PARP inhibitors in BRCA mutation-associated ovarian cancer.

Lancet Oncol 2015 Jan 4;16(1):10-2. Epub 2014 Dec 4.

Institute of Cancer Sciences, The Christie and University of Manchester, Withington, Manchester M20 4BX, UK. Electronic address:

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S147020451471172
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(14)71172-6DOI Listing
January 2015

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.

Clin Cancer Res 2014 Sep 19;20(17):4549-4558. Epub 2014 Jun 19.

Translational Angiogenesis Group, University of Manchester and Christie Hospital, Wilmslow Road, Withington, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3248DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154862PMC
September 2014

Angiogenesis as a target for the treatment of ovarian cancer.

Curr Opin Oncol 2013 Sep;25(5):558-65

Institute for Cancer Studies, Christie Hospital, University of Manchester, Withington, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e328363e0daDOI Listing
September 2013

Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics.

Histopathology 2012 Sep 11;61(3):454-64. Epub 2012 Jun 11.

Department of Pathology, Manchester Royal Infirmary, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2559.2012.04247.xDOI Listing
September 2012

Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.

Int J Gynecol Cancer 2011 Jan;21(1):58-65

Department of Medical Oncology, The Christie NHS Foundation Trust, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0b013e3182049273DOI Listing
January 2011

Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.

Cancer Biol Ther 2010 Sep 4;10(5):495-504. Epub 2010 Sep 4.

Cancer Research UK and University of Manchester Dept. Translational Angiogenesis, Paterson Institute, Withington, Manchester, UK.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040972PMC
http://dx.doi.org/10.4161/cbt.10.5.12585DOI Listing
September 2010

Imaging angiogenesis of genitourinary tumors.

Nat Rev Urol 2010 Feb 19;7(2):69-82. Epub 2010 Jan 19.

Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2009.262DOI Listing
February 2010

Angiogenesis as a therapeutic target in cancer.

Clin Med (Lond) 2008 Aug;8(4):455-8

Christie Hospital Foundation NHS Trust, Manchester.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4952946PMC
http://dx.doi.org/10.7861/clinmedicine.8-4-455DOI Listing
August 2008

Antiangiogenic therapy for ovarian cancer.

Curr Opin Oncol 2007 Sep;19(5):497-505

Cancer Research UK and University of Manchester, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32827035f0DOI Listing
September 2007

A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis.

Expert Opin Ther Targets 2006 Dec;10(6):867-76

Christie Hospital, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.10.6.867DOI Listing
December 2006

The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate.

J Biol Chem 2006 May 15;281(21):14813-22. Epub 2006 Feb 15.

Department of Medical Oncology, Cancer Research UK and the University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M512400200DOI Listing
May 2006

Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium.

Clin Cancer Res 2005 Jun;11(12):4282-8

Cancer Research UK Department of Medical Oncology, Christie Hospital and Paterson Institute, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-1386DOI Listing
June 2005

Profiling heparan sulfate proteoglycans in ovarian carcinoma.

ScientificWorldJournal 2005 Mar;5:230-3

Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1100/tsw.2005.31DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936526PMC
March 2005

Assessment of therapeutic response in patients with metastatic bone disease.

Lancet Oncol 2004 Oct;5(10):607-16

Cancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(04)01596-7DOI Listing
October 2004

Management of the menopause in cancer survivors.

Cancer Treat Rev 2002 Dec;28(6):321-33

Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Ont., Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0305-7372(02)00089-0DOI Listing
December 2002

Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies.

Lancet Oncol 2002 Oct;3(10):611-9

Department of Medical Oncology, Christie Hospital, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1470-2045(02)00875-6DOI Listing
October 2002